4 results
To evaluate whether dGEMRIC is suitable as outcome measure to detect changes over time, and also between intervention groups in patients with OA of the knee.
To assess whether there is (cost) effectiveness over a period of 1 year of additive intra-articular injections with a high molecular HA derivate in patients with OA of the knee.
To prevent avoidable visual impairment, in our controlled study, we want to contribute to the evidence of good treatment effects on visual functions (visual acuity both distances near and at distance, accuracy of accommodation), prevention of…
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.